文献速递帕金森病与运动障碍认知障碍与痴呆

帕金森病中的蛋白病变与纵向认知下降

Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease.
PubMed 文献 · Neurology · 2022-04-13

本研究纳入帕金森病患者152例和对照52例,分析脑脊液α-突触核蛋白、tau、β-淀粉样蛋白42、β-淀粉样蛋白PET及APOE基因型与纵向认知下降的关系。基线脑脊液β-淀粉样蛋白预测记忆和整体认知下降,APOE ε4+者视空间功能下降更快,β-淀粉样蛋白PET预测所有认知指标下降;三种β-淀粉样蛋白相关指标均预测痴呆转化时间,其中PET模型拟合最佳。

要点

  • 基线脑脊液β-淀粉样蛋白预测记忆(p=0.04)和整体认知(p=0.01)下降。
  • APOE ε4+者较ε4-者视空间功能下降更快(p=0.03)。
  • 基线β-淀粉样蛋白PET预测所有认知指标下降(均p≤0.004),且模型拟合最佳。

核心结论

  • β-淀粉样蛋白积聚的存在或风险一致预测帕金森病患者的认知下降和痴呆转化时间,提示β-淀粉样蛋白有潜力作为帕金森病认知变化的预后指标和生物标志物。

研究设计与样本

  • 纵向研究纳入帕金森病患者152例和对照52例,完成脑脊液蛋白分析(α-突触核蛋白、总tau、β-淀粉样蛋白42)、β-淀粉样蛋白PET扫描和/或APOE基因型检测,并进行纵向整体认知和痴呆状态评估及注意力、语言、记忆、视空间和执行功能测试;采用分层线性增长模型和Cox比例风险模型分析。

主要发现

  • 基线脑脊液β-淀粉样蛋白预测记忆下降(p=0.04)和整体认知功能下降(p=0.01)。
  • APOE基因型显示显著组间效应,ε4+个体较ε4-个体视空间功能下降更快(p=0.03)。
  • 基线β-淀粉样蛋白PET显著预测所有认知指标下降(均p≤0.004)。
  • 基线脑脊液α-突触核蛋白和tau均未预测认知下降。
  • 三种β-淀粉样蛋白相关指标(脑脊液、PET、APOE)均预测痴呆转化时间,其中以β-淀粉样蛋白PET为预测因子的模型拟合数据最佳。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: People with Parkinson disease (PD) commonly experience cognitive decline, which may relate to increased α-synuclein, tau, and β-amyloid accumulation. This study examines whether the different proteins predict longitudinal cognitive decline in PD. METHODS: All participants (PD n = 152, controls n = 52) were part of a longitudinal study and completed a lumbar puncture for CSF protein analysis (α-synuclein, total tau [tau], and β-amyloid42 [β-amyloid]), a β-amyloid PET scan, and/or provided a blood sample for APOE genotype (ε4+, ε4-), which is a risk factor for β-amyloid accumulation. Participants also had comprehensive, longitudinal clinical assessments of overall cognitive function and dementia status, as well as cognitive testing of attention, language, memory, and visuospatial and executive function. We used hierarchical linear growth models to examine whether the different protein metrics predict cognitive change and multivariate Cox proportional hazard models to predict time to dementia conversion. Akaike information criterion was used to compare models for best fit. RESULTS: Baseline measures of CSF β-amyloid predicted decline for memory (p = 0.04) and overall cognitive function (p = 0.01). APOE genotypes showed a significant group (ε4+, ε4-) effect such that ε4+ individuals declined faster than ε4- individuals in visuospatial function (p = 0.03). Baseline β-amyloid PET significantly predicted decline in all cognitive measures (all p ≤ 0.004). Neither baseline CSF α-synuclein nor tau predicted cognitive decline. All 3 β-amyloid--related metrics (CSF, PET, APOE) also predicted time to dementia. Models with β-amyloid PET as a predictor fit the data the best. DISCUSSION: Presence or risk of β-amyloid accumulation consistently predicted cognitive decline and time to dementia in PD. This suggests that β-amyloid has high potential as a prognostic indicator and biomarker for cognitive changes in PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Myers PS, O'Donnell JL, Jackson JJ, et al. Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. Neurology. 2022. PMID: 35418463. doi:10.1212/WNL.0000000000200344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。